These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25392858)

  • 1. Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.
    Cattaneo D; Baldelli S; Castoldi S; Charbe N; Cozzi V; Fucile S; Clementi E
    AIDS; 2014 Oct; 28(16):2477-80. PubMed ID: 25392858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
    Cusini A; Vernazza PL; Yerly S; Decosterd LA; Ledergerber B; Fux CA; Rohrbach J; Widmer N; Hirschel B; Gaudenz R; Cavassini M; Klimkait T; Zenger F; Gutmann C; Opravil M; Günthard HF;
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):28-35. PubMed ID: 23018371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
    Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
    AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
    Slish J; Ma Q; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Forrest A; Brazeau D; Boston NS; Catanzaro L; DiFrancesco R; Morse GD
    Ther Drug Monit; 2007 Oct; 29(5):560-5. PubMed ID: 17898644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
    Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
    J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital.
    Engelbrecht AE; Wiesner L; Norman J; Rabie H; Decloedt EH
    J Trop Pediatr; 2020 Aug; 66(4):385-394. PubMed ID: 31754710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
    Winston A; Bloch M; Carr A; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S
    J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.
    Loutfy MR; Walmsley SL; Klein MB; Raboud J; Tseng AL; Blitz SL; Pick N; Conway B; Angel JB; Rachlis AR; Gough K; Cohen J; Haase D; Burdge D; Smaill FM; de Pokomandy A; Loemba H; Trottier S; la Porte CJ
    BMC Infect Dis; 2013 Jun; 13():256. PubMed ID: 23732043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
    Di Biagio A; Prinapori R; Giannarelli D; Maggiolo F; Di Giambenedetto S; Borghi V; Penco G; Cicconi P; Francisci D; Sterrantino G; Zoncada A; Monno L; Capetti A; Giacometti A;
    J Antimicrob Chemother; 2013 Jan; 68(1):200-5. PubMed ID: 22915463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring.
    Goicoechea M; Vidal A; Capparelli E; Rigby A; Kemper C; Diamond C; Witt MD; Haubrich R;
    Antivir Ther; 2007; 12(1):55-62. PubMed ID: 17503748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
    Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C
    J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
    J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
    Moltó J; Deig E; Valle M; Maria Llibre J; Miranda C; Cedeño S; Valero S; Negredo E; Clotet B
    Ther Drug Monit; 2010 Feb; 32(1):93-6. PubMed ID: 20040897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
    Barreiro P; Rodríguez-Novoa S; Labarga P; Ruiz A; Jiménez-Nácher I; Martín-Carbonero L; Gonzalez-Lahoz J; Soriano V
    J Infect Dis; 2007 Apr; 195(7):973-9. PubMed ID: 17330787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
    Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
    Regazzi M; Villani P; Gulminetti R; Cusato M; Brandolini M; Tinelli C; Barassi A; Maserati R; Sighinolfi L; D'Arminio Monforte A; Melzi D'Eril GV
    Ther Drug Monit; 2011 Jun; 33(3):303-8. PubMed ID: 21544015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
    Cattaneo D; Baldelli S; Cozzi V; Fusi M; Atzori C; Micheli V; Filice C; Gervasoni C
    Ther Drug Monit; 2020 Apr; 42(2):330-334. PubMed ID: 31743292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
    Gervasoni C; Meraviglia P; Minisci D; Ferraris L; Riva A; Landonio S; Cozzi V; Charbe N; Molinari L; Rizzardini G; Clementi E; Galli M; Cattaneo D
    PLoS One; 2015; 10(4):e0123670. PubMed ID: 25875091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.